A detailed history of Parallel Advisors, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Parallel Advisors, LLC holds 28 shares of VRDN stock, worth $509. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28
Holding current value
$509
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$12.16 - $23.33 $340 - $653
28 New
28 $0

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $726M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.